Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety.

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Abstract Text:

Michael H Silverman,Mary Lynne Hedley,K Ulrich Petry,Jeffrey S Weber,

OBJECTIVE.: Trial designs for novel nonsurgical, nonablative therapies for cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) must ensure patient safety while providing sufficient time to show clinical effects. We propose an observation period based on literature and current practice. MATERIALS AND METHODS.: We reviewed 3 types of literature regarding observation of untreated CIN 2,3: 1) the management of CIN in pregnancy, perhaps the best existing model of observation; 2) the natural history of untreated CIN 2,3; and 3) the optimal means of protecting patient safety during longer-term follow-up of untreated CIN 2,3 lesions. RESULTS.: Data from both the pregnant and nonpregnant patient populations indicate that delaying treatment of CIN for periods of several weeks to several months is rarely associated with clinically significant disease progression. Screening and follow-up criteria that promote patient safety have been suggested and seem adaptable to clinical trials. CONCLUSIONS.: Careful screening and follow-up of patients with CIN 2,3 allows an observation period of at least 6 months after nonsurgical, nonablative therapy in clinical trials.

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Publishing Authors By Initials

MH Silverman,ML Hedley,KU Petry,JS Weber,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of lower genital tract disease

VOLUME: 6

Page Numbers: 206-11

Journal Abbreviation:

ISSN: 1089-2591

DAY: 19

MONTH: Oct

YEAR: 2002

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9704963

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety.

AFFILIATION: 1BioStrategics Consulting Ltd, Marblehead, MA; 2ZYCOS Incorporated, Lexington, MA; 3Frauenklinik der Medizischen Hochschule, Hannover, Germany; and 4Keck/University of Southern California School of Medicine, Los Angeles, CA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Low Genit Tract Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety Related Publications

• ATP synthase--the structure of the stator stalk.
• Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease.
• Assessment of contamination by polychlorinated biphenyls and aliphatic and aromatic hydrocarbons in sediments of the Santos and São Vicente Estuary System, São Paulo, Brazil.
• Bowel symptoms in women planning surgery for pelvic organ prolapse.
• Chemokines: inflammatory mediators of atherosclerosis.
• Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety.
• Controlling the electrochemically active area of carbon fiber microelectrodes by the electrodeposition and selective removal of an insulating photoresist.
• Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury.
• Differential localization of the Dictyostelium kinase DPAKa during cytokinesis and cell migration.
• Effect of rhBMP-2 on guided bone regeneration in humans.
• Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of Saccharopolyspora erythraea.
• Electrochemical investigation of Pb2+ binding and transport through a polymerized crystalline colloidal array hydrogel containing benzo-18-crown-6.
• Endoanal ultrasound findings and fecal incontinence symptoms in women with and without recognized anal sphincter tears.
• FDA regulation of allogeneic islets as a biological product.
• High-throughput method for lipophilicity measurement.
• Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements.
• Inflammatory mediators in atherosclerotic vascular disease.
• Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage.
• Perfusion MRI in CNS disease: current concepts.
• Physical activity in women planning sacrocolpopexy.
• RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.
• Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
• Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B.
• Renal effects of opioid exposure: considerations for therapeutic use.
• Rydberg fingerprint spectroscopy of hot molecules: structural dispersion in flexible hydrocarbons.
• Selective cancer cell killing by alpha-tocopheryl succinate.
• Simultaneous maximization of cell permeabilization and viability in single-cell electroporation using an electrolyte-filled capillary.
• TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation.
• The conserved TFLK motif of mammary-associated serum amyloid A3 is responsible for up-regulation of intestinal MUC3 mucin expression in vitro.
• alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization.